Long-Term, Open-Label Study of the Safety and Efficacy of Atomoxetine in Adults With Attention-Deficit/Hyperactivity Disorder: An Interim Analysis
J Clin Psychiatry 2005;66(3):294-299
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
disorder (ADHD) is an early-onset neuropsychiatric disorder that
affects 3% to 7% of school-age children and 4% of adults. Its
pathophysiology is thought to involve the dopaminergic and
noradrenergic pathways associated with attention control and
impulsivity. These symptoms have largely been defined in the
childhood population, but the course of the condition and
expression in the adult population are not as well characterized.
Method: This is an ongoing, 3-year, open-label
study consisting of adults with DSM-IV ADHD who were previously
enrolled in 1 of 2 double-blind, acute-treatment studies of
atomoxetine. The results of the interim analysis reported here
were derived from the study of 384 patients at 31 sites who had
been studied for a period of up to 97 weeks. The primary efficacy
measure was the Conners' Adult ADHD Rating Scale-Investigator
Rated: Screening Version (CAARS-Inv:SV) total ADHD symptom score.
In addition, safety, adverse events, and vital sign measurements
Results: Significant improvement was noted with
atomoxetine therapy, with mean CAARS-Inv:SV total ADHD symptom
scores decreasing 33.2% from 29.2 (baseline of open-label
therapy) to 19.5 (endpoint of open-label therapy) (p < .001).
Similar and significant decreases were noted for the secondary
efficacy measures. Adverse events consisted primarily of
pharmacologically (noradrenergic) expected effects, such as
increases in heart rate and blood pressure and a slight decrease
Conclusion: The results of this interim analysis
of an ongoing, open-label study of adults with ADHD support the
long-term efficacy, safety, and tolerability of atomoxetine for
the treatment of adult ADHD.